Evatanepag

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameEvatanepag
Drug Alias Name依伐奈帕Evatanepagum依凡坦帕CP-533536
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid EP2 receptor agonists
TargetsProstanoid EP2 receptor
Therapy Area/IndicationsTibial Fractures
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBosnia and HerzegovinaCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsTibial Fractures

Other Information

ATC CodeN/A
Related LinksKEGG